Global Leading Market Research Publisher QYResearch Announces the Release of Its Latest Report: “Short-acting GLP-1 Therapy – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”
The global diabetes therapeutics landscape continues to evolve at a remarkable pace, driven by rapid innovation in incretin therapies, expanding patient populations, and rising demand for precision glycemic control. QYResearch’s new report, “Short-acting GLP-1 Therapy – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”, provides a comprehensive analysis of market trends from 2021–2025 and strategic forecasts from 2026–2032, delivering actionable insights for pharmaceutical executives, investors, clinical decision-makers, and market strategists.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6117127/short-acting-glp-1-therapy
Market Overview
The global market for Short-acting GLP-1 Therapy was valued at US$ 35,960 million in 2025 and is projected to reach US$ 119,570 million by 2032, registering a robust CAGR of 19.0%. While this market remains smaller and more price-sensitive than its long-acting counterparts, it continues to occupy critical clinical niches, particularly in post-prandial glucose (PPG) management and settings where rapid titration or GI tolerability are major considerations.
In 2024, global production reached approximately 92,961 K units, with an average market price of US$ 362 per unit. Production primarily includes immediate-release injectable formulations, with emerging oral GLP-1 analogs gaining traction in select markets.
Product Definition and Clinical Applications
Short-acting GLP-1 therapy comprises glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with brief systemic exposure, typically lasting hours rather than days. Administered once- or twice-daily, these agents are designed to:
- Blunt post-meal glucose spikes by slowing gastric emptying
- Enhance glucose-dependent insulin secretion
- Support adjunctive therapy with basal insulin
Compared with long-acting GLP-1 analogs, short-acting therapies produce modest reductions in fasting glucose and weight, but remain essential for prandial glycemic control, particularly in:
- Early-line type 2 diabetes treatment in cost-constrained markets
- Peri-prandial use in inpatient or acute-care settings
- Patient populations intolerant to weekly agents
Industry Value Chain
The short-acting GLP-1 market operates along a highly specialized, vertically integrated chain:
1. Upstream:
- Peptide starting materials (protected amino acids, coupling reagents)
- Solid-phase peptide synthesis equipment
- Purification systems (prep HPLC)
- Device components (pens, cartridges, safety needles)
- Stabilizing excipients
2. Midstream:
- Originator and biosimilar manufacturers formulate immediate-release injections.
- Fill-finish operations integrate CMC programs, device human factors, and stability testing.
- Contract manufacturing organizations (CMOs) / CDMOs increasingly supply peptide APIs and aseptic filling services, enabling scale-out from originators.
3. Downstream:
- Endocrinology and primary-care channels, diabetes clinics, and hospital formularies drive adoption.
- Payers influence treatment persistence through tiering and step therapy.
- Retail, mail-order pharmacies, and specialty distributors manage fulfillment and device training.
- Digital diabetes platforms provide adherence nudges and titration guidance, enhancing real-world outcomes.
Market Drivers
1. Strategic Clinical Niche:
Short-acting GLP-1 therapies excel in post-prandial glucose management, complementing basal insulin therapy or acting as first-line incretins where cost or supply constraints limit long-acting agent use.
2. Rapid Titration and Reversibility:
The short systemic exposure allows fast dose adjustments, essential in hospital, peri-operative, or inpatient settings, particularly for patients with gastrointestinal sensitivity.
3. Price Sensitivity and Accessibility:
Lower acquisition costs compared with weekly agents make these therapies attractive in emerging markets and for payer segments seeking cost-effective solutions.
4. Proven Clinical Familiarity:
Daily GLP-1 pens are widely known among clinicians and patients, which reduces adoption barriers and supports continued market demand.
Market Constraints
Despite these advantages, short-acting GLP-1 therapies face significant headwinds:
- Competition from long-acting agents and next-generation incretin combinations with superior weight-loss and cardiometabolic outcomes
- Patient preference for less frequent dosing, particularly in high-income regions
- Growing obesity-focused indications, which favor weekly or dual-agonist molecules
- Real-world adherence challenges, requiring investment in patient education and digital support
Competitive strategies focus on:
- Value-based pricing
- Fixed-ratio co-formulations with basal insulin
- Hospital and peri-operative protocols
- Lifecycle management initiatives, such as pen usability, cold-chain robustness, and CGM-based post-prandial evidence
Economic Profile
Short-acting GLP-1s exhibit:
- Lower list prices than long-acting counterparts, with higher rebate pressures
- Lower manufacturing complexity, as peptide chains are shorter and devices simpler
- Margins stabilized through competitive pricing, reliable supply, and evidence generation
Regional and Strategic Outlook
High-income regions:
- Short-acting GLP-1s primarily adjunctive therapy for PPG control, often integrated into fixed-ratio insulin protocols
- Volume growth is modest, offset by switching to weekly or dual-agonist therapies
Cost-sensitive or emerging markets:
- Remain first-line incretin options, especially where weekly analogs are unaffordable
- Growth supported by market expansion, payer alignment, and local guideline adoption
Manufacturers that combine competitive pricing, supply reliability, user-friendly devices, and CGM-based post-prandial evidence are expected to retain market share and achieve stable margins, even as the market gradually shifts toward long-acting therapies.
Key Players
Leading Global Manufacturers:
- Sanofi
- AstraZeneca
- Amneal Pharmaceuticals
Product Segments:
- Injection
- Oral
Applications:
- Type 2 Diabetes
- Obesity / Weight Management
- Other metabolic indications
Future Outlook
The short-acting GLP-1 therapy market will continue to evolve through 2032, reflecting:
- Strategic adoption in PPG-dominant patient populations
- Expansion in cost-sensitive and emerging markets
- Integration into fixed-ratio basal insulin programs and inpatient protocols
- Continuous innovation in devices, cold-chain logistics, and digital support platforms
Investors, clinical leaders, and pharmaceutical executives can leverage these insights to identify growth pockets, optimize lifecycle management, and align product offerings with evolving clinical needs.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
